Abdulrafeh Naqash to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
4.656
-
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023 Oct; 11(10).
Score: 0.799
-
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. 2021 Dec 01; 7(12):1856-1861.
Score: 0.704
-
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020 Jul; 69(7):1177-1187.
Score: 0.624
-
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer. 2019 07 05; 7(1):169.
Score: 0.596
-
Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. Acta Oncol. 2018 06; 57(6):867-872.
Score: 0.535
-
Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol. 2018 05; 57(5):705-708.
Score: 0.533
-
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022 08 15; 128(16):3067-3079.
Score: 0.183
-
Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology. 2022; 11(1):2017162.
Score: 0.177
-
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 12; 20(12):2577-2584.
Score: 0.173
-
Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer? JCO Precis Oncol. 2021; 5.
Score: 0.167
-
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol. 2020 12 01; 6(12):1952-1956.
Score: 0.164